The FLT3-ITD mutation, previously described in AML patients with this genetic aberration, can be seen as an upstream mechanism in HIF-1 activation, even though the mTOR pathway increases HIF-1 levels [205]. This evidence concerns the gene MTOR and acute myeloid leukemia.